Understanding MF-CTCL

Actor portrayal.

Mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) is a rare type of blood cancer that mainly affects the skin. It is the most common type of cutaneous T-cell lymphoma. MF-CTCL occurs when certain white blood cells, called T-cells, become cancerous and start to collect in the skin instead of staying in the bloodstream. These cells cause changes in the skin that can look like common conditions such as eczema or psoriasis, which is why it may take years to get a proper diagnosis.

Although MF-CTCL is a rare type of blood cancer, you are not alone. Approximately 18,000 to 20,000 people in the United States are diagnosed with MF-CTCL. Of those people, approximately 1,200 to 1,400 people are diagnosed with early-stage MF-CTCL per year.


What MF-CTCL may look like

While MF-CTCL typically affects areas of the skin that are not regularly exposed to sunlight (eg, the torso, buttocks, hips, and armpits), it may occur anywhere on the body.

Artistic rendition of Stage IA/IB MF-CTCL as Patches

Stage IA/Patch

Artistic rendition of Stage IA/IB MF-CTCL as Plaques

Stage IB/Plaque

Artistic rendition of Stage IA/IB MF-CTCL as Hypopigmentation

Stage IA/IB/Hypopigmentation

Actual patient examples. Individual patient presentations may vary. Images used with permission from VisualDx.

What are the early stages of MF-CTCL?

MF-CTCL is staged to describe how much of your skin is affected by patches or plaques and whether the disease has spread beyond the skin or not. Both Stage IA and IB MF-CTCL are considered early stages and are limited to the skin only. While MF-CTCL may look different based on skin types, most people manage early-stage MF-CTCL with skin-directed treatments.

Stage IA: patches and/or plaques cover up to 10% of the skin

Stage IB: patches and/or plaques cover 10% to 79% of the skin

Diagram comparing Stage IA (~10% skin coverage) and Stage IB (~30% skin coverage) MF-CTCL, with patches/plaques shown in purple on two body silhouettes. Diagram comparing Stage IA (~10% skin coverage) and Stage IB (~30% skin coverage) MF-CTCL, with patches/plaques shown in purple on two body silhouettes.

For illustrative purposes only. Percentages and appearance may vary depending on a person's body type and size.